Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence
-
Letto da:
-
Di:
A proposito di questo titolo
We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.
Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer.
Topics include:
- Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrence
- Balancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatment
Discussants:
Neil M. Iyengar, MD
Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD
Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Sponsored by Lilly